Guangdong New South Group

Guangdong New South Group is a diversified Chinese conglomerate with a significant focus on the pharmaceutical and healthcare sectors, particularly in the development and global distribution of anti-malarial treatments. The company is best known for its flagship product, Artequick, a fourth-generation artemisinin-based combination therapy (ACT) developed in collaboration with the Guangzhou University of Chinese Medicine. New South Group has gained international recognition for its 'Fast Elimination of Malaria by Source Eradication' (FEMSE) strategy, which has been successfully implemented in several African nations, including the Comoros and Malawi. Beyond pharmaceuticals, the group operates in traditional Chinese medicine, health-related real estate, and energy, positioning itself as a major player in the 'Belt and Road' initiative's health cooperation efforts.